Adaptive Biotechnologies Corporation (FRA:1HM)
13.40
-1.16 (-8.00%)
At close: Dec 5, 2025
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $93.97M USD in the quarter ending September 30, 2025, with 102.38% growth. This brings the company's revenue in the last twelve months to $252.75M, up 42.57% year-over-year. In the year 2024, Adaptive Biotechnologies had annual revenue of $178.96M with 5.10% growth.
Revenue (ttm)
$252.75M
Revenue Growth
+42.57%
P/S Ratio
8.99
Revenue / Employee
$408.33K
Employees
619
Market Cap
1.94B EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Adaptive Biotechnologies News
- 4 days ago - Chad Robins Sells 160,734 Shares of Adaptive Biotechnologies Corp - GuruFocus
- 11 days ago - Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test at Hematology Conference - GuruFocus
- 12 days ago - Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting - Wallstreet:Online
- 12 days ago - Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting - GlobeNewsWire
- 23 days ago - Chad Robins Sells 89,265 Shares of Adaptive Biotechnologies Corp - GuruFocus
- 24 days ago - Adaptive Biotechnologies (ADPT): Morgan Stanley Raises Price Target to $16 | ADPT Stock News - GuruFocus
- 4 weeks ago - Adaptive Biotechnologies Corporation 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - JP Morgan Raises Price Target for Adaptive Biotechnologies (ADPT) to $20 | ADPT Stock News - GuruFocus